# Paul Emery

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/paul-emery/

## Facts

| Field | Value |
| --- | --- |
| Citations | 130,110 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 159 |
| i10-index | 790 |
| Last Known Institution | University of Leeds |
| OpenAlex ID | https://openalex.org/A5018678002 |
| ORCID iD | https://orcid.org/0000-0002-7429-8482 |
| Works | 1,619 |

## Researcher papers

Showing 12 of 20.

- [2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative](https://scholariq.org/papers/2010-rheumatoid-arthritis-classification-criteria-an-american-college-of-2/)
- [Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis](https://scholariq.org/papers/infliximab-and-methotrexate-in-the-treatment-of-rheumatoid-arthritis/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-2/)
- [Rheumatoid arthritis](https://scholariq.org/papers/rheumatoid-arthritis-2/)
- [Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial](https://scholariq.org/papers/infliximab-chimeric-anti-tumour-necrosis-factor-monoclonal-antibody-versus/)
- [Treating rheumatoid arthritis to target: recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-recommendations-of-an-international-task/)
- [Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks](https://scholariq.org/papers/rituximab-for-rheumatoid-arthritis-refractory-to-anti-tumor-necrosis-factor/)
- [\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](https://scholariq.org/papers/neular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-2014-update-of-the-recommendations-of-an/)
- [Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci](https://scholariq.org/papers/genome-wide-association-study-meta-analysis-identifies-seven-new-rheumatoid/)
- [IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial](https://scholariq.org/papers/il-6-receptor-inhibition-with-tocilizumab-improves-treatment-outcomes-in/)
- [American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials](https://scholariq.org/papers/american-college-of-rheumatology-european-league-against-rheumatism-provisional/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [University of Leeds](https://scholariq.org/institutions/university-of-leeds/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.